763
Views
11
CrossRef citations to date
0
Altmetric
Research Article

Neuroprotection by herbal formula FBD and its active compounds

, , &
Pages 608-614 | Received 03 Feb 2008, Accepted 19 Jun 2008, Published online: 22 Jun 2009

Figures & data

Figure 1. Chemical structures of atractylenolide I, II, III, ferulic acid, levistolid A, and pachymic acid.

Figure 1.  Chemical structures of atractylenolide I, II, III, ferulic acid, levistolid A, and pachymic acid.

Figure 2. Effects of FBD, FBD-CO2 and FBD-H2O on brain infarction and circulating NSE efflux in ICR mice subjected to cerebral repetitive I/R. Each column represents mean ± SD of 6 mice. NSE, neuron specific enolase; I/R, ischemia-reperfusion; #p<0.05, ##p<0.01 vs the sham-operated group; *p<0.05, **p<0.01 vs the saline-pretreated I/R group.

Figure 2.  Effects of FBD, FBD-CO2 and FBD-H2O on brain infarction and circulating NSE efflux in ICR mice subjected to cerebral repetitive I/R. Each column represents mean ± SD of 6 mice. NSE, neuron specific enolase; I/R, ischemia-reperfusion; #p<0.05, ##p<0.01 vs the sham-operated group; *p<0.05, **p<0.01 vs the saline-pretreated I/R group.

Figure 3. Neuroprotective activities of atractylenolide II, atractylenolide III, levistolid A, ferulic acid from FBD-CO2 on PC12 cells I/R-like insults. Each dot represents mean ± SD of 6 wells. I/R, ischemia-reperfusion; *p<0.05, **p<0.01 vs the vechicle-treated PC12 cells.

Figure 3.  Neuroprotective activities of atractylenolide II, atractylenolide III, levistolid A, ferulic acid from FBD-CO2 on PC12 cells I/R-like insults. Each dot represents mean ± SD of 6 wells. I/R, ischemia-reperfusion; *p<0.05, **p<0.01 vs the vechicle-treated PC12 cells.

Figure 4. Neuroprotective activities of atractylenolide I, II, III, levistolid A, ferulic acid and pachymic acid combination on PC12 cells I/R-like insults. Values are means ± SD of three different experiments. The A570/650 in control was 0.64 ± 0.02. I/R, ischemia-reperfusion; Ctl, Control; Vh, vehicle; Com, Combination; CO2, FBD-CO2; VE, Vitamin E; ##p < 0.01 vs the control (Ctl); **p<0.01, ***p < 0.001 vs the vehicle (Vh)-treated cells; ††p < 0.01 vs the FBD-CO2-treated cells.

Figure 4.  Neuroprotective activities of atractylenolide I, II, III, levistolid A, ferulic acid and pachymic acid combination on PC12 cells I/R-like insults. Values are means ± SD of three different experiments. The A570/650 in control was 0.64 ± 0.02. I/R, ischemia-reperfusion; Ctl, Control; Vh, vehicle; Com, Combination; CO2, FBD-CO2; VE, Vitamin E; ##p < 0.01 vs the control (Ctl); **p<0.01, ***p < 0.001 vs the vehicle (Vh)-treated cells; ††p < 0.01 vs the FBD-CO2-treated cells.

Table 1. Neuroprotections (%) of atractylenolide I,II, III, levistolid A, ferulic acid and pachymic acid alone or in combination on PC12 cells I/R-like insults induced by Na2S2O4, MSG, H2O2 and KCl in assay I–IV in vitro.

Figure 5. Effects of FBD-CO2 and its six compounds combination on brain infarction and circulating NSE efflux in ICR mice subjected to cerebral repetitive I/R. Each column represents mean ± SD of 6 mice. NSE, neuron specific enolase; I/R, ischemia-reperfusion; #p<0.05, ##p<0.01 vs the sham-operated group; *p<0.05, **p<0.01 vs the saline-pretreated I/R group.

Figure 5.  Effects of FBD-CO2 and its six compounds combination on brain infarction and circulating NSE efflux in ICR mice subjected to cerebral repetitive I/R. Each column represents mean ± SD of 6 mice. NSE, neuron specific enolase; I/R, ischemia-reperfusion; #p<0.05, ##p<0.01 vs the sham-operated group; *p<0.05, **p<0.01 vs the saline-pretreated I/R group.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.